OVERVIEW   |   TEAM  |   NEWS

A new generation of purification technologies

Advances in biotechnology have led to a rapid increase in the diversity of drug modalities that are now treating and curing diseases once thought to be intractable; worldwide revenues from commercialized biologics now exceed $200 billion per annum.
While scientific advances have enabled the prospect of these therapies, realizing their full industrialization and reduced cost of goods will require new technologies to enable manufacturers to overcome challenges of process and facility inefficiencies, delayed development and commercialization timelines.
At Avitide, we do not believe that one affinity purification ligand fits all and we have addressed purification challenges by developing a proprietary portfolio of AVIPure™ affinity ligands as diverse as our partners’ therapeutics. Specific challenges require specific solutions. We have now optimized an innovative, end-to-end affinity purification platform, working with our partners from concept through commercial resin supply, to deliver unparalleled affinity purification performance and long-term value.

To date, we have delivered affinity purification solutions across the following categories:

Biospecific Antibodies Fc Fusions
 
Growth Factors, Insulins, Hormones
 
Recombinant & Viral Vaccines
 
Gene Therapies
 
Cell-based Therapies
 
Product vs. Product-Impurity Separations
 
Process Analytical Technologies
 

Affinity resins are affordable –
Avitide partnerships have delivered

Simply put – Purity and yield drive favorable manufacturing economics.  Avitide is the industry’s premiere biopharmaceutical affinity purification partner, delivering significant value by:
Providing reliable, consistent, and scalable manufacturing solutions
. . . . . . . . . . . . . . .

Ensuring purity and yield goals are met early in development

  • Derisks commercial manufacturing line of sight
  • Increases overall speed of development to reach the clinic and market
  • Avoids development challenges commonly encountered with novel therapeutic modalities
  • Integrates with CDMO development services

. . . . . . . . . . . . . . .

Improving commercial economic viability and drug accessibility through cost efficiencies
. . . . . . . . . . . . . . .

Expanding exclusive intellectual property around biologics via new manufacturing process patents
. . . . . . . . . . . . . . .

Establishing multi-product facilities with similar operational architecture to antibody production facilities
. . . . . . . . . . . . . . .

Improving overall facility productivity and leverage of existing CAPEX investments
. . . . . . . . . . . . . . .

Enabling fully continuous downstream processing of novel biologic modalities

 

1-2 yrs

for our partners to break even on FTE savings alone

$4-6M

total cost savings from reduction in FTEs associated with process development activities

2-8x

decrease in $/kilogram due to improved process economics
Rapid development and multi-product facilities enables accelerated development timelines, multiple CMOs

2-6x

increase in facility productivity due to improved manufacturing productivity
Integrated Continuous Downstream Processing enables Multiple continuous purification operations

16 Cavendish Court
Lebanon, NH 03766

603.965.2100
email us

© 2019 Avitide
All Rights Reserved